Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Wedbush Reiterates Outperform on Cidara Therapeutics (CDTX) Following 2Q
August 16, 2016 8:21 AM EDTWedbush reiterated an Outperform rating and $22.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the company's 2Q. CDTX reported a net loss of ($11.9M) or ($0.85)/share, below the consensus of ($0.76), on higher than expected R&D costs.
Analyst David Nierengarten commented, "With CD101... More
BTIG Expects More Visibility for Cidara Therapeutics' (CDTX) CD101 Soon; Affirms at 'Buy'
August 15, 2016 11:48 AM EDTBTIG affirms Cidara Therapeutics, Inc. (Nasdaq: CDTX) at Buy with a price target of $24 following recent quarterly results and CD101 update.
Analyst Timothy Chiang commented, We expect more visibility on the Co.s novel echinocandin (antifungal) product candidate, CD101, by early 2017 when... More
